Kellie Combs, Ropes & Gray life sciences partner, analyzes three documents released by the FDA outlining the agency's current thinking regarding drug and device manufacturers' communication of information not contained in FDA-approved labeling.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.